Multi-Disciplinary Approach Needed for Congenital and Childhood DM Care

The results of a new MDF-funded study on the impact of congenital myotonic dystrophy are now available from Dr. Nicholas Johnson of the University of Utah and colleagues. The high frequency of social and cognitive issues in their findings underline the need for a multi-disciplinary approach to care. 

The Impact of Pregnancy on Myotonic Dystrophy: A Registry-Based Study

Many common DM symptoms become more severe during pregnancy, and women with DM have higher than average miscarriage rates, according to a study commissioned by MDF that examined data from the Myotonic Dystrophy Family Registry and the National Registry for DM and FSHD.

Myotonic Dystrophy Anesthesia Guidelines

Anesthesia raises special risks to those living with myotonic dystrophy (DM), as the disease results in heightened sensitivity to sedatives and analgesics.

Common Symptoms of DM2 and Their Impact on Daily Living

Researchers from the University of Rochester recently published a paper examining the symptoms and impact of myotonic dystrophy type 2 (DM2). They found that the most commonly reported symptoms of DM2 are not, in fact, the ones that have the highest reported impact on daily living.

MDF SAC Member Profile: Dr. Kathie Bishop

MDF is pleased to welcome Dr. Kathie Bishop, Ph.D., to its Scientific Advisory Committee(SAC). Dr. Bishop, who joined the SAC in summer 2015, is a seasoned expert in neurological and neuromuscular research and drug development.

MDF SAC Member Profile: Dr. Laura Ranum

MDF is pleased to welcome Laura Ranum to its Scientific Advisory Committee (SAC). Dr. Ranum, who joined the SAC in summer 2015, is an internationally known investigator of disorders that result from repeat expansion mutations, such as those that cause type 1 and type 2 myotonic dystrophy (DM1 and DM2).

Benefit/Risk Study Results: Focus on Muscle Weakness

The Myotonic Dystrophy Foundation partnered with Silicon Valley Research Group to develop a survey to better understand how people with DM weigh the benefits of new treatments again the risks. 

MDF SAC Member Profile: Dr. Thomas Cooper

MDF is pleased to welcome Tom Cooper, MD, to our Scientific Advisory Committee (SAC). Dr. Cooper, who joined the SAC in summer 2015, is a renowned myotonic dystrophy (DM) investigator whose laboratory has made major contributions to understanding the molecular pathogenesis of the disease and pointing the way toward rational therapeutic development.

Experts Participate in DM Regulatory Workshop

MDF hosted the Myotonic Dystrophy Patient-Centered Therapy Development Meeting in Washington, D.C. on September 17, 2015. The regulatory workshop featured speakers from academia, industry and the FDA. 

Evolving Strategies Using Oligonucleotides for DM1

Conjugation of morpholino phosphorodiamidate oligomer (PMO) ASOs to a cell-penetrating peptide improves their bioavailability and efficacy in skeletal muscle of a DM1 model.

© Myotonic Dystrophy Foundation. All rights reserved.